Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report.
Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy. These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and  capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena. Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other "consumption coagulopathies." This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery. This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH. The corresponding clinical event was characterized by marked hypertension and abrupt neurological deterioration.
D000208:Acute Disease; D000368:Aged; D000614:Aminocaproates / Q000009:adverse effects*; D015119:Aminocaproic Acid / Q000009:adverse effects*; D005260:Female; D006801:Humans; D012008:Recurrence; D012077:Renal Artery / Q000473:pathology; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy* / Q000473:pathology; D013927:Thrombosis / Q000139:chemically induced* / Q000473:pathology
D000614:Aminocaproates; D015119:Aminocaproic Acid